Skip to main content
SpringerLink
Log in

Population Pharmacokinetics of Tirilazad: Effects of Weight, Gender, Concomitant Phenytoin, and Subarachnoid Hemorrhage

  • Published:
Pharmaceutical Research Aims and scope Submit manuscript

Abstract

Purpose. Data collected during Phase I and II in the development of tirilazad were pooled and analyzed using nonlinear mixed effects models to assess covariates which might affect tirilazad pharmacokinetics.

Methods. Four single dose and five multiple dose studies in normal volunteers were combined with two multiple dose studies performed in patients with subarachnoid hemorrhage (SAH) to identify factors related to intersubject variability in clearance (CL) and central compartment volume (Vc). Data from 253 subjects, which consisted of 7,219 tirilazad concentrations, were analyzed. The effects of weight, gender, patient versus volunteer status, and phenytoin use were evaluated.

Results. Relative to male volunteers not receiving concomitant phenytoin, significant effects on clearance included: a 46% increase in volunteers receiving phenytoin, and an 82% increase in clearance associated with SAH patients (all of whom received phenytoin). Significant effects on Vc were: a 26% increase for female volunteers not receiving phenytoin, a 12% decrease for volunteers receiving concomitant phenytoin, a 152% increase for male SAH patients, and a 270% increase for female SAH patients. Incorporating patient covariate effects substantially reduced the interindividual variability (from 27.9% to 24.7% for clearance and from 48.2% to 37.5% for Vc). Residual variability was estimated at 66% coefficient of variation (CV) in SAH patients and at 22−48% CV over the range of predicted concentrations in normal volunteers.

Conclusions. The most important factors affecting tirilazad pharmacokinetics are the administration of phenytoin (increased CL) and SAH (increased Vc and residual variability). The effect of gender on tirilazad pharmacokinetics was modest.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

REFERENCES

  1. J. M. Braughler, E. D. Hall, J. Jacobsen, J. M. McCall, and E. D. Means. The 21-aminosteroids: potent inhibitors of lipid peroxidation for the treatment of central nervous system trauma and ischemia. Drugs Future 14:143–152 (1989).

    Google Scholar 

  2. N. F. Kassell, E. C. Haley, W. M. Alves, C. A. Hansen, B. Weir, and the participants. Phase two trial of tirilazad in aneurysmal subarachnoid hemorrhage. Can. J. Neurol. Sci. 20(Suppl 1):S29 (1993).

    Google Scholar 

  3. N. F. Kassell, E. C. Haley, C. Apperson-Hansen, W. M. Alves, and the participants. A randomized, double-blind, vehicle-controlled trial of tirilazad mesylate in patients with aneurysmal subarachnoid hemorrhage; a cooperative study in Europe/Australia/New Zealand. J. Neurosurg. 84:221–228 (1996).

    Google Scholar 

  4. J. C. Fleishaker, L. K. Hulst, and G. R. Peters. Multiple dose tolerability and pharmacokinetics of tirilazad mesylate at doses of up to 10 mg/kg/day administered over 5–10 days in healthy volunteers. Int. J. Clin. Pharmacol. Ther. 32:223–230 (1994).

    Google Scholar 

  5. L. C. Wienkers, R. C. Steenwyk, P. E. Sanders, and P. G. Pearson. Biotransformation of tirilazad in human: 1. Cytochrome P450 3A-mediated hydroxylation of tirilazad mesylate in human liver microsomes. J. Pharmacol. Exp. Ther. 277:982–990 (1996).

    Google Scholar 

  6. J. C. Fleishaker, L. K. Hulst, and G. R. Peters. The effect of phenytoin on the pharmacokinetics of tirilazad mesylate in healthy male volunteers. Clin Pharmacol Ther 56:389–397 (1994).

    Google Scholar 

  7. J. C. Fleishaker, L. K. Pearson, and G. R. Peters. Phenytoin causes a rapid increase in 6β-hydroxycortisol urinary excretion in humans—a putative measure of CYP3A induction. J. Pharm. Sci. 84:292–294 (1995).

    Google Scholar 

  8. J. C. Fleishaker, L. K. Hulst-Pearson, and G. R. Peters. Gender does not affect the degree of induction of tirilazad clearance by phenobarbital. Eur. J. Clin. Pharmacol. 50:139–145 (1996).

    Google Scholar 

  9. J. C. Fleishaker, P. G. Pearson, L. C. Wienkers, L. K. Pearson, and G. R. Peters. Biotransformation of tirilazad in human: 2. Effect of ketoconazole on tirilazad clearance and oral bioavailability. J. Pharmacol. Exp. Ther. 277:991–998 (1996).

    Google Scholar 

  10. L. K. Hulst, J. C. Fleishaker, G. R. Peters, J. D. Harry, D. M. Wright, and P. Ward. Effect of age and gender on tirilazad pharmacokinetics in humans. Clin. Pharmacol. Ther. 55:378–384 (1994).

    Google Scholar 

  11. J. C. Fleishaker, L. K. Hulst-Pearson, and G. R. Peters. Effect of gender and menopausal status on the pharmacokinetics of tirilazad mesylate in healthy subjects. Am. J. Ther. 2:553–560 (1995).

    Google Scholar 

  12. J. C. Fleishaker, R. N. Straw, and C. J. Cross. Pharmacokinetics of tirilazad and U-89678, an active, reduced metabolite, following acute head trauma in adults. J. Pharm. Sci. 86:434–437 (1997).

    Google Scholar 

  13. E. C. Haley, N. F. Kassell, C. Apperson-Hansen, M. H. Maile, W. M. Alves, and the participants. A randomized, double-blind, vehicle-controlled trial of tirilazad mesylate in patients with aneurysmal subarachnoid hemorrhage: a cooperative study in North America. J. Neurosurg. 86:467–474 (1997).

    Google Scholar 

  14. J. C. Fleishaker, G. R. Peters, K. S. Cathcart, and R. C. Steenwyk. Evaluation of the pharmacokinetics and tolerability of tirilazad mesylate, a 21-aminosteroid free radical scavenger: II. Multiple-dose administration. J. Clin. Pharmacol. 33:182–190 (1993).

    Google Scholar 

  15. J. C. Fleishaker, G. R. Peters, and K. S. Cathcart. Evaluation of the pharmacokinetics and tolerability of tirilazad mesylate, a 21-aminosteroid free radical scavenger: I. Single-dose administration. J. Clin. Pharmacol. 33:175–181 (1993).

    Google Scholar 

  16. J. C. Fleishaker, L. K. Hulst, and G. R. Peters. Lack of a pharmacokinetic/pharmacodynamic interaction between nimodipine and tirilazad mesylate in healthy volunteers. J. Clin. Pharmacol. 34:837–841 (1994).

    Google Scholar 

  17. J. C. Fleishaker, L. K. Hulst, and G. R. Peters. Lack of pharmacokinetic interaction between cimetidine and tirilazad mesylate. Pharm. Res. 11:341–344 (1994).

    Google Scholar 

  18. L. K. Hulst, J. C. Fleishaker, and G. R. Peters. Single dose proportionality of tirilazad mesylate pharmacokinetics in healthy male volunteers. Pharm. Res. 10(Suppl 1):S334 (1993).

    Google Scholar 

  19. L. K. Pearson, J. C. Fleishaker, and G. R. Peters. Comparison of the pharmacokinetics of tirilazad mesylate in healthy volunteers and stable subjects with mild liver cirrhosis. Eur. J. Clin. Pharmacol. 50:299–304 (1996).

    Google Scholar 

  20. J. C. Fleishaker and G. R. Peters. Pharmacokinetics of tirilazad in healthy male subjects at doses above 6 mg/kg/day. Int. J. Clin. Pharmacol. Ther. 35:28–32 (1997).

    Google Scholar 

  21. S. L. Beal and L. B. Sheiner, eds. NONMEM User's Guides, NONMEM Project Group, University of California at San Francisco, San Francisco, 1992.

    Google Scholar 

  22. J. C. Fleishaker, L. K. Pearson, and G. R. Peters. Induction of tirilazad clearance by phenytoin. Biopharm. Drug. Disp. 19:91–96 (1998).

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Clinical Pharmacokinetics Unit, Pharmacia & Upjohn, Kalamazoo, Michigan, 49007

    Joseph C. Fleishaker

  2. Pharmaceutical Outcomes Research, Inc., Buffalo, New York

    Jill Fiedler-Kelly & Thaddeus H. Grasela

Authors
  1. Joseph C. Fleishaker
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jill Fiedler-Kelly
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Thaddeus H. Grasela
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Joseph C. Fleishaker.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fleishaker, J.C., Fiedler-Kelly, J. & Grasela, T.H. Population Pharmacokinetics of Tirilazad: Effects of Weight, Gender, Concomitant Phenytoin, and Subarachnoid Hemorrhage. Pharm Res 16, 575–583 (1999). https://doi.org/10.1023/A:1018835516040

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1018835516040

Search

Navigation